Liquidia (LQDA) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Veradermics is the larger company by market cap ($5.04 billion vs $4.90 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | MANE |
|---|---|---|
| Share price | $54.43 | $119.52 |
| Market cap | $4.90B | $5.04B |
| 1-day change | -3.88% | -3.92% |
| YTD return | +57.81% | — |
| 1-year return | +86.98% | — |
| 5-year return | +1224.33% | — |
| Forward P/E | 15.12 | — |
| EPS (TTM) | $-1.05 | $-3.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | — |
| Revenue growth (YoY) | +1031.18% | — |
| Net income (latest FY) | $-68.92M | $-70.00M |
| Operating margin | -32.45% | — |
| Net margin | -43.53% | — |
| 52-week high | $93.61 | $156.63 |
| 52-week low | $22.31 | $32.00 |
| Distance from 52-week high | -41.85% | -23.69% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +21.50% | +56.74% |
| Average volume | 3.52M | 738.22K |
| Shares outstanding | 90.11M | 42.20M |
| Employees | 216 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
LQDA vs MANE FAQ
Which is bigger, Liquidia or Veradermics?
Veradermics (MANE) is larger, with a market capitalization of $5.04B compared with $4.90B for Liquidia (LQDA).
Are Liquidia and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.